Hepatic encephalopathy
Conditions
Interventions
Test group:live combined bifidobacterium and lactobacillus tablets
Control group:Placebo
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Patients with cirrhosis who have had at least one episode of overt hepatic encephalopathy (HE) (West-haven HE>=2) in the past 6 months, excluding hepatic encephalopathy episodes that were considered to be caused by gastrointestinal bleeding, drugs, dialysis for renal failure, or central nervous system injury; 3. West-Haven HE was 0 or 1 at enrollment, and the Model for End-Stage Liver Disease (MELD) score was less than or equal to 25. 4. Patients who voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, lung, kidney (creatinine > 177umol/L), blood, endocrine system, and mental and nervous system diseases; 2. Include those who plan to undergo liver transplantation within 1 month; 3. Those who underwent transjugular intrahepatic portosystemic shunt within the first 3 months; 4. Severe hypokalemia (K<2.5mmol.L); 5. Serious infection occurs; 6. Gastrointestinal bleeding at the time of inclusion and after inclusion; 7. Those who have allergies and idiosyncratic reactions to Bifidobacterium Lactobacillus triple viable bacteria tablets.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of hepatic encephalopathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| hospitalization rate;serum bilirubin level;serum albumin level;alanine aminotransferase level;aspartate aminotransferase level;Endotoxin Level;fecal flora;Blood ammonia levels; | — |
Countries
China
Contacts
Public ContactYang Wenjuan
West China Hospital, Sichuan University
Outcome results
None listed